The global Digital Biomarkers Market is moving toward a healthcare model where patient data can be captured continuously through devices people already use. Digital Biomarkers Market valued at USD 3.4 billion in 2023, the market is projected to reach USD 13.9 billion by 2030, expanding at a CAGR of 22.3% from 2024 to 2030. North America held the largest revenue share of 58.4% in 2023, while Asia Pacific is expected to register the fastest growth.

Why Are Digital Biomarkers Becoming Important in Healthcare?

Traditional healthcare measurements often depend on clinical visits, laboratory testing, or scheduled assessments. Digital biomarkers introduce another approach by enabling health-related information to be captured through smartphones, wearable sensors, mobile applications, and other digital technologies.

These tools can detect signals such as breathing, speech, heat, eye movements, heart rate, oxygen saturation, sleep patterns, and other patient-related measurements. Their ability to support continuous and remote monitoring is increasing their relevance across healthcare and clinical research.

Can Smartphones and Wearables Become Healthcare Monitoring Tools?

Increasing smartphone penetration and the expanding availability of smartwatches, medical bracelets, and fitness trackers are creating a larger technology base for digital biomarkers.

Download a free sample report or claim your copy of this full market intelligence report

Vocal digital biomarkers are also emerging as an important area of development. Audio recordings captured through smartphones can potentially provide information for risk prediction, diagnosis, and remote monitoring while placing relatively little burden on patients. The launch of CoLive Voice by the Luxembourg Institute of Health illustrates the growing focus on this approach.

Which Type of Digital Biomarker Is Leading the Market?

Wearable technology represented the largest type segment, accounting for 39.6% of revenue in 2023. New healthcare-focused wearables and continued product launches are supporting demand for devices capable of collecting health information.

At the same time, mobile-based applications are developing even faster. This segment is expected to register a CAGR of 24.7% during the forecast period. Growing internet usage, expanding mHealth adoption, and increasing use of smartphones for health management are supporting this momentum.

Why Are Digital Biomarkers Attracting Clinical Trial Researchers?

Clinical research is increasingly looking for ways to collect measurements remotely and continuously. Wearable sensors and digital algorithms can provide information about patient activity and biometrics without requiring every assessment to take place at a clinical site.

The rising cost of drug research and relatively low development success rates are strengthening interest in technologies that can improve the efficiency of decentralized clinical studies. Digital biomarkers can support research involving conditions such as Alzheimer's disease and dementia by providing additional measurements during the study process.

Which Clinical Practice Is Driving Digital Biomarker Adoption?

Diagnostic digital biomarkers dominated the market in 2023. Their use is expanding across cardiovascular diseases, mental health, neurological disorders, diabetes, and other disease categories where digital measurements can support diagnosis and monitoring.

Monitoring digital biomarkers, however, are expected to experience the fastest growth. Increasing investment in smartwatches and wearable technology is improving access to health-related information, including heart rate, sleep, and disease-specific biometrics.

Why Is Cardiovascular Monitoring Such an Important Application?

Cardiovascular and metabolic diseases represented the largest therapeutic-area segment in 2023. The prevalence of cardiovascular disorders and the growing number of digital health applications are supporting the use of digital biomarkers in this area.

The neurological disorders segment is expected to grow fastest. Increasing disease prevalence and the development of algorithms capable of extracting information about brain activity are encouraging new applications. Partnerships such as Koneksa and Beacon Biosignals' clinical-trial collaboration demonstrate how digital biomarkers are being explored for neurological research.

Can Digital Biomarkers Support Personalized Healthcare?

The ability to continuously collect patient information creates opportunities for more individualized monitoring and care. Healthcare companies accounted for the largest end-use share in 2023 as they increasingly integrate digital measurements into clinical care and research.

Payers are expected to record the fastest growth. Insurance organizations can use digital biomarkers to understand patient needs and support individualized care plans, including processes related to prior authorization.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

What Is Holding Back the Digital Biomarkers Market?

Despite strong growth potential, adoption faces several challenges. Limited awareness and a shortage of skilled professionals can restrict market development, particularly in regions where digital biomarker expertise is less established.

Data privacy is another important consideration. Regulatory requirements influence hardware, software, digital endpoint validation, privacy, security, and interoperability. These factors can affect how quickly digital biomarker solutions are adopted across healthcare environments.

Which Region Is Leading the Digital Biomarkers Market?

North America held the largest market share of 58.4% in 2023, supported by R&D investment, leading market participants, smart-device adoption, product launches, and healthcare infrastructure initiatives. The U.S. accounted for 67.9% of the regional market in 2023.

Asia Pacific is expected to grow at the fastest pace, supported by aging populations, chronic disease prevalence, smartphone penetration, wearable adoption, and expanding digital healthcare services. China and Japan are developing their digital monitoring capabilities, while India and other emerging markets are also benefiting from healthcare digitalization.

Who Is Shaping the Competitive Landscape?

Companies are pursuing product launches, partnerships, acquisitions, collaborations, and geographic expansion to strengthen their positions. The market has also witnessed notable M&A activity, including Huma's acquisition of Alcedis to expand its digital clinical trial capabilities.

Key companies identified in the market include ActiGraph LLC, AliveCor Inc., Koneksa, Altoida Inc., and Amgen Inc.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Where Could the Next Growth Opportunities Come From?

The future of the digital biomarkers market is closely linked to the continued development of wearables, mobile health applications, remote monitoring, decentralized clinical trials, and digital healthcare infrastructure.

As healthcare systems seek more continuous measurements and researchers look for efficient ways to capture real-world patient information, digital biomarkers are positioned to become increasingly important across diagnosis, monitoring, clinical research, and personalized care.

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.